FDA Approves BRINSUPRI™ (brensocatib) as the First and Only Treatment for Non-Cystic Fibrosis Bronchiectasis, a Serious, Chronic Lung Disease

— Approximately 500,000 U.S. Patients Are Diagnosed with Non-Cystic Fibrosis Bronchiectasis (NCFB), a Progressive Disease That Can Lead to Permanent Lung Damage —— BRINSUPRI 10 mg and 25 mg Doses Approved for the Treatment of NCFB —— BRINSUPRI, a First-in-Class DPP1 Inhibitor Targeting Neutrophilic Inflammation, Is Available by Prescription Through a Comprehensive Specialty Pharmacy Network —— Insmed to Host Investor Conference Call Today at 12:00 PM ET  —BRIDGEWATER, N.J., Aug. 12, 2025 /PRNewswire/ -- Ins ...